Saegis Pharmaceuticals logo — company profile

Saegis Pharmaceuticals

Founded 1999 Series B Total: $44.00M Biopharma, Biotechnology +1

General Information

Company Name Saegis Pharmaceuticals
Founded Year 1999
Industries Biopharma, Biotechnology, Health Care
Funding Stage Series B
Social

Get notified when Saegis Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Saegis Pharmaceuticals

Saegis Pharmaceuticals, established in 1999, is a biopharmaceutical company headquartered in Half Moon Bay, California. Specializing in the development of medications for behavioral disorders, the company boasts a robust pipeline targeting central nervous system diseases characterized by cognitive dysfunction. This includes conditions such as Alzheimer’s disease, mild cognitive impairment, ADHD, and cognitive impairment linked to schizophrenia. Saegis Pharmaceuticals' CNS therapeutics aim to address memory loss and cognitive deficits associated with aging, psychiatric disorders, and brain trauma. The company recently secured a significant $30.00M Series B investment on 17 November 2003, with participation from a notable group of investors including Polaris Partners, Sofinnova Partners, Technology Partners, Sofinnova Investments, Versant Ventures, and Neuro Ventures. With its focus on developing medications for conditions with substantial unmet medical needs, Saegis Pharmaceuticals is positioned to make a meaningful impact in the biopharmaceutical and healthcare industries.

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 6
Investor Investor Investor Investor Investor Investor
17 Nov 2003
Series A •••••• 1
Investor
01 Jan 2001

Saegis Pharmaceuticals Alternatives & Competitors

Saegis Pharmaceuticals vs
Cognigenics
Cognigenics United States

Shaping the Future of Genetic Medicines for Mental Health and Neurocognitive Disorders

Seed
20 employees
Health and Wellness
Saegis Pharmaceuticals vs

The Gold Standard of Impairment Testing

21 employees
Digital Health, Privacy and Security
Saegis Pharmaceuticals vs
Evoke Neuroscience
Evoke Neuroscience United States

Leaders in computational EEG for brain health. Builders of tools to aid physicians in diagnosing cog...

16 employees
Health Care, Medical Devices

FAQ About Saegis Pharmaceuticals

Saegis Pharmaceuticals focuses on developing medications for behavioral disorders. The company has a robust pipeline targeting central nervous system diseases that involve cognitive dysfunction such as Alzheimer’s disease, mild cognitive impairment, ADHD, and cognitive impairment linked to schizophr...
Saegis Pharmaceuticals was founded in 1999.
Saegis Pharmaceuticals operates in the following industries: Biopharma, Biotechnology, Health Care.
Saegis Pharmaceuticals has completed 2 funding rounds, raising a total of $44.00M. The latest funding stage is Series B.
Top alternatives and competitors to Saegis Pharmaceuticals include Cognigenics, Impairment Science, Inc., Evoke Neuroscience, The Cognitive and Research Center of New Jersey, LLC, The NeuroCognitive and Behavioral Institute. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Saegis Pharmaceuticals and Cognigenics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Saegis Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy